<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JDM</journal-id><journal-title-group><journal-title>Journal of Diabetes Mellitus</journal-title></journal-title-group><issn pub-type="epub">2160-5831</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jdm.2015.54027</article-id><article-id pub-id-type="publisher-id">JDM-60653</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Prevalence and Risk Factors of Hypertension in Type 2 Diabetics in Benin
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>aniel</surname><given-names>Amoussou-Guenou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Armand</surname><given-names>Wanvoegbe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Anthelme</surname><given-names>Agbodandé</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Alihonou</surname><given-names>Dansou</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yessoufou</surname><given-names>Tchabi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yasmine</surname><given-names>Eyissè</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Arnaulde</surname><given-names>Amoussou-Guenou Fandi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Latif</surname><given-names>Moussé</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>Clinique d’Akpakpa, Cotonou, Benin</addr-line></aff><aff id="aff2"><addr-line>Polyclinique Atinkanmey, Cotonou, Benin</addr-line></aff><aff id="aff3"><addr-line>CHUD-OP, Porto-Novo, Benin</addr-line></aff><aff id="aff1"><addr-line>Banque d’insuline, Cotonou, Benin</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>wafinarm@yahoo.fr(AW)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>09</month><year>2015</year></pub-date><volume>05</volume><issue>04</issue><fpage>227</fpage><lpage>232</lpage><history><date date-type="received"><day>18</day>	<month>June</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>25</month>	<year>October</year>	</date><date date-type="accepted"><day>28</day>	<month>October</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: Couple High Blood Pressure (HBP)-Diabetes is a morbid association and a public 
  health problem. The aim of this study was to determine the actual epidemiological profile of HBP in type 2 diabetic. Methods: A 
  cross-sectional, prospective, descriptive and analytical study was 
  conducted at 
  Banque d’insuline of Cotonou, Polyclinique Atinkanmey and CHUD-Ou&#233;m&#233;-Plateau. 
  The study took place over a period of 06 months from March 01 to August 30, 2014. The study included patients with type 2 diabetes mellitus seen at consultation who agreed to participate in the study. 
  Results: The survey involved 400 individuals. Among them, 34% were male and the sex ratio was 0.48. The mean age was 55.6 &#177; 10.3 years (range 28 - 87 years). The prevalence of hypertension in type 2 diabetic patients was 70%. The risk factors significantly associated with HBP were age above 55 years (p = 0.000), abdominal obesity (p = 0.036), a diabetes duration above 10 years (p = 0.009). Complications significantly associated with HBP were stroke (p = 0.013) and diabetic foot (p = 0.044). Conclusion: HBP-type 2 Diabetes association is frequent in Benin.
 
</p></abstract><kwd-group><kwd>Diabetes</kwd><kwd> Prevalence</kwd><kwd> Risk Factors</kwd><kwd> Benin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Diabetes mellitus (DM) represents a global public health challenge. Its prevalence particularly the prevalence of type 2 diabetes mellitus is improving in the world.</p><p>DM affects 381.8 million persons in the world according to IDF estimations in 2013 [<xref ref-type="bibr" rid="scirp.60653-ref1">1</xref>] . IDF estimates that the number of diabetics will reach 591.9 million in 2035, a 55.0% ascension [<xref ref-type="bibr" rid="scirp.60653-ref1">1</xref>] . Complications linked with that important risk factor will also increase because of the rise of its principal risk factor as obesity. The last obesity risk of HBP worsens the prognosis of diabetic patient by increasing the cardiovascular risk and chronic com- plications [<xref ref-type="bibr" rid="scirp.60653-ref2">2</xref>] . HBP represents a very frequent co-morbidity, affecting 20% to 60% of diabetics in the world [<xref ref-type="bibr" rid="scirp.60653-ref3">3</xref>] . Detection and treatment of HBP in diabetic patients are the more effective measures for prevention of related complications. The aim of this study was to determine the actual epidemiological profile of HBP in type 2 diabetic in Benin.</p></sec><sec id="s2"><title>2. Patients and Methods</title><sec id="s2_1"><title>2.1. Framework and Nature of the Study</title><p>This cross-sectional, prospective, descriptive and analytical study was performed at Banque d’insuline of Cotonou, Polyclinique Atinkanmey and CHUD-Ou&#233;m&#233;-Plateau. The study took place over a period of 06 months from Marsh 01 to August 30, 2014.</p><p>Created in January 1996, “Banque d’insuline” is the main center of diagnosis and ambulatory follow-up of diabetes mellitus in Cotonou. “Polyclinique Atinkanmey” is a private hospital in Cotonou where several specialist doctors carry out medical consultations. CHD OP is the Teaching Hospital of Porto-Novo City.</p></sec><sec id="s2_2"><title>2.2. Studied Population and Data Collection</title><p>Were included, the type 2 diabetes followed as outpatients in the different centers studied.</p><p>We have included all type 2 diabetics who were consulted by diabetologists who participate to the study (two diabetologists).</p><p>During the six months that the study lasted, 400 people were included.</p><p>Included Patients were assessed using a survey form designed for this purpose. The clinical records of these patients were also used for the collection of additional data.</p><p>Blood pressure was taken in all patients using an electronic sphygmomanometer (OMRON<sup>&#174; </sup>Blood Pressure Monitor) after five minutes of rest.</p></sec><sec id="s2_3"><title>2.3. Studied Variables</title><p>Were studied:</p><p> Socio-demographic characteristics: age, sex, occupation, place of residence, marital status;</p><p> Tensional Profile: hypertension was defined by the blood pressure higher or equal to 140/90 mmHg, or pre- hypertension;</p><p> Obesity: were considered obese people with BMI ≥ 30 kg/m<sup>2</sup>;</p><p> Abdominal obesity: abdominal obesity was defined using IDF 2005 standards (waist circumference ≥ 94 cm in Men and ≥80 cm in Women);</p><p> Characteristic of type 2 diabetes: duration of diabetes, diabetes imbalance;</p><p> Complications or other associated risk factors: dyslipidemia, micro albuminuria, diabetic neuropathy, diabetic retinopathy, stroke, diabetic foot, ischemia cardiopathy.</p></sec><sec id="s2_4"><title>2.4. Statistical Analysis</title><p>Data were entered and analyzed using SPSS 18.0 software. Categorical variables were expressed as a percentage and quantitative variables averaged together with a standard deviation.</p><p>The relation between HBP and investigated factors was studied by calculating the Odd Ratio (OR) with 95% confidence interval.</p><p>We used the Chi-square test for the comparison of the percentages. A p value &lt; 0.05 was considered significant.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. General Characteristics</title><p>Women represent 66% of the study population. Sex-ratio is 0.52. Mean age of patients was 55.6 &#177; 10.3 years with extremes of 28 to 87 years. Three hundred and eighty four patients (95%) lived in urban city. Customers are the more represented with a 52.5% proportion. Three hundred and nineteen patients (79.8%) lived in couple. The diabetes was balanced (HbA1c &lt; 7%) in 31.28% of 243 patients who tested HbA1c.</p></sec><sec id="s3_2"><title>3.2. Frequency of HBP</title><p>Frequency of HBP by measure at consultation in diabetic patients was 70% (see <xref ref-type="table" rid="table1">Table 1</xref>).</p></sec><sec id="s3_3"><title>3.3. Risk Factors (<xref ref-type="table" rid="table2">Table 2</xref>)</title><p>1) Gender</p><p>Gender would not be a factor related to HBP occurrence in type 2 diabetics (p = 0.059).</p><p>2) Age</p><p>Age above 55 years look significantly associated with occurrence of HBP in type 2 diabetics (p = 0.000). Frequency of HBP in diabetic patients aged less than 55 years was at 50.5% while it was at 86.2% diabetics aged above 55 years.</p><p>3) Seniority diabetes</p><p>The diabetes duration vary from 1 year to 33 years with a mean duration at 8.27 &#177; 6.78 years. The older is the diabetes, the higher is the risk to develop HBP. The frequency of HBP in diabetic who has less than 10 years of diabetes duration was at 64.1%. Between 10 - 20 years duration of diabetes, it was at 77.3% (p = 0.009). Frequency of HBP in type 2 diabetic who has more than 20 years of diabetes duration was at 91.7%. (p = 0.006).</p><p>4) Abdominal obesity</p><p>Abdominal obesity is significantly associated with occurrence of HBP in type 2 diabetics (p = 0.036). The frequency of HBP in diabetics with abdominal obesity was at 71.8% while it was at 57.1% in those without abdominal obesity.</p><p>5) Dyslipidemia</p><p>Dyslipidemia do not feel to be associated with occurrence of HBP in type 2 diabetics (p = 0.426).</p><p>6) Diabetes imbalance</p><p>Diabetes imbalance do not seem to influence occurrence of HBP in type 2 diabetics (p = 0.198).</p><p>7) Degenerative complications of diabetes</p><p>Among degenerative complications of diabetes only stroke (p = 0.013) and diabetic foot (p = 0.044) seem to be linked with HBP in our study.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>There was preeminence of female diabetics (66%) in our study population with sex-ratio at 0.52. The result was comparable with Jimoh et al.’s (62%) [<xref ref-type="bibr" rid="scirp.60653-ref4">4</xref>] and Adebisi et al.’s (60%) in Nigeria [<xref ref-type="bibr" rid="scirp.60653-ref5">5</xref>] . This female preeminence is probably explained by a more marked care of female than male about health. Male would consult less often for silent disease like diabetes mellitus and HBP. Preeminence in male was noticed by Dibia in Nigeria [<xref ref-type="bibr" rid="scirp.60653-ref6">6</xref>] .</p><p>Mean age of patients was at 55.6 &#177; 10.3 years with extremes of 28 to 87 years. Two hundred and eighteen patients (54.5%) were older than 55 years. This mean age in our study is similar to those of Dibia in Nigeria (58.5 years) [<xref ref-type="bibr" rid="scirp.60653-ref6">6</xref>] , Ralison et al. in Madagascar (51 years) [<xref ref-type="bibr" rid="scirp.60653-ref7">7</xref>] and Lokrou et al. in Ivory Cost (49.67 years) [<xref ref-type="bibr" rid="scirp.60653-ref8">8</xref>] .</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Prevalence of HBP in diabetics</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Tensional Profile</th><th align="center" valign="middle" >Number</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >HBP</td><td align="center" valign="middle" >280</td><td align="center" valign="middle" >70%</td></tr><tr><td align="center" valign="middle" >No HBP</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" >30%</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >400</td><td align="center" valign="middle" >100%</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Summary of relation between HBP and investigated factors</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Factors</th><th align="center" valign="middle"  colspan="2"  >HBP</th><th align="center" valign="middle"  rowspan="2"  >OR</th><th align="center" valign="middle"  rowspan="2"  >IC (95%)</th><th align="center" valign="middle"  colspan="2"   rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >Absent</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Sex</td><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >49</td><td align="center" valign="middle"  rowspan="2"  >0.6</td><td align="center" valign="middle"  rowspan="2"  >0.4 - 1.0</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.059</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >193</td><td align="center" valign="middle" >71</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Age</td><td align="center" valign="middle" >&lt;55 years</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >90</td><td align="center" valign="middle"  rowspan="2"  >6.1</td><td align="center" valign="middle"  rowspan="2"  >3.8 - 9.3</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.000</td></tr><tr><td align="center" valign="middle" >≥55 years</td><td align="center" valign="middle" >118</td><td align="center" valign="middle" >30</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Abdominal obesity</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >252</td><td align="center" valign="middle" >99</td><td align="center" valign="middle"  rowspan="2"  >1.9</td><td align="center" valign="middle"  rowspan="2"  >1.0 - 3.5</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.036</td></tr><tr><td align="center" valign="middle" >Absent</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >21</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >BMI</td><td align="center" valign="middle" >&lt; 25</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >25 - 29.99</td><td align="center" valign="middle" >102</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >0.4 - 1.3</td><td align="center" valign="middle" >0.350</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥30</td><td align="center" valign="middle" >115</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >0.8 - 2.2</td><td align="center" valign="middle" >0.510</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Dyslipidemia</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >28</td><td align="center" valign="middle"  rowspan="2"  >1.3</td><td align="center" valign="middle"  rowspan="2"  >0.7 - 2.3</td><td align="center" valign="middle"  rowspan="2"  >0.426</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Absent</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Duration of diabetes</td><td align="center" valign="middle" >&lt;10 years</td><td align="center" valign="middle" >159</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >10 - 20 years</td><td align="center" valign="middle" >99</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >1.9</td><td align="center" valign="middle" >1.2 - 3.1</td><td align="center" valign="middle" >0.009</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;20 years</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >1.4 - 26.8</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Diabetes imbalance</td><td align="center" valign="middle" >HbA1c ≥ 7</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" >50</td><td align="center" valign="middle"  rowspan="2"  >0.6</td><td align="center" valign="middle"  rowspan="2"  >0.3 - 1.2</td><td align="center" valign="middle"  rowspan="2"  >0.198</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >HbA1c &lt; 7</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Micro albuminuria 24 h</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >14</td><td align="center" valign="middle"  rowspan="2"  >1.5</td><td align="center" valign="middle"  rowspan="2"  >0.7 - 3.2</td><td align="center" valign="middle"  rowspan="2"  >0.380</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Absent</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Diabetic neuropathy</td><td align="center" valign="middle" >Pr&#233;sent</td><td align="center" valign="middle" >214</td><td align="center" valign="middle" >90</td><td align="center" valign="middle"  rowspan="2"  >1.1</td><td align="center" valign="middle"  rowspan="2"  >0.7 - 1.8</td><td align="center" valign="middle"  rowspan="2"  >0.759</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Absent</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Diabetic retinopathy</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >08</td><td align="center" valign="middle"  rowspan="2"  >2.1</td><td align="center" valign="middle"  rowspan="2"  >0.9 - 4.8</td><td align="center" valign="middle"  rowspan="2"  >0.131</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Absent</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Stroke</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >00</td><td align="center" valign="middle"  rowspan="2"  >1.4</td><td align="center" valign="middle"  rowspan="2"  >1.3 - 1.5</td><td align="center" valign="middle"  rowspan="2"  >0.013</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Absent</td><td align="center" valign="middle" >266</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Diabetic foot</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >03</td><td align="center" valign="middle"  rowspan="2"  >3.4</td><td align="center" valign="middle"  rowspan="2"  >1.0 - 11.1</td><td align="center" valign="middle"  rowspan="2"  >0.044</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Absent</td><td align="center" valign="middle" >257</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Ischemia cardiopathy</td><td align="center" valign="middle" >Present</td><td align="center" valign="middle" >08</td><td align="center" valign="middle" >02</td><td align="center" valign="middle"  rowspan="2"  >1.5</td><td align="center" valign="middle"  rowspan="2"  >0.3 - 7</td><td align="center" valign="middle"  rowspan="2"  >0.729</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Absent</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>HbA1c: glycated hemoglobin; OR: odd ratio; CI: confidence interval.</p><p>The prevalence of HBP in type 2 diabetics in our study was at 70%. This high frequency is similar to those reported by Howards et al. in 2006 in Canada (70%) [<xref ref-type="bibr" rid="scirp.60653-ref9">9</xref>] , Dibia in 2009 in Nigeria (71.6%) [<xref ref-type="bibr" rid="scirp.60653-ref6">6</xref>] , Lokrou et al. in 2009 in Ivory Cost (76.82%) [<xref ref-type="bibr" rid="scirp.60653-ref8">8</xref>] and Tanguy et al. in 2012 in Limoges (75%) [<xref ref-type="bibr" rid="scirp.60653-ref10">10</xref>] .</p><p>Contrary to our study, other authors reported lower frequencies of HBP in type 2 diabetes. In this way, Dembele et al. reported 16.7% in Bamako in 2000 [<xref ref-type="bibr" rid="scirp.60653-ref11">11</xref>] , Ralison et al. reported 39.63% in Madagascar in 2007 [<xref ref-type="bibr" rid="scirp.60653-ref7">7</xref>] , Ntyonga-Pono reported 40.67% in Gabon in 1996 [<xref ref-type="bibr" rid="scirp.60653-ref12">12</xref>] and Louda et al. reported 54.4% in Marocco in 2010 [<xref ref-type="bibr" rid="scirp.60653-ref13">13</xref>] . This difference of frequency would be linked to the methodology used by the authors. In fact, those studies were retrospective and some authors used old WHO criterions of diagnosis for HBP (160/95 mmHg). It could explain the low frequency of HBP in diabetics in those studies.</p><p>We didn’t identify gender as risk factor for HBP in type 2 diabetes in our study (p = 0.059), but the frequency of HBP in female was higher (73.1%) than in male (64%). Dibia didn’t identify gender as risk factor for HBP in type 2 diabetes [<xref ref-type="bibr" rid="scirp.60653-ref6">6</xref>] .</p><p>Adverse results were reported by Dembele et al. [<xref ref-type="bibr" rid="scirp.60653-ref11">11</xref>] and Ralison et al. [<xref ref-type="bibr" rid="scirp.60653-ref7">7</xref>] who identified female sex as risk factor for HBP in type 2 diabetes.</p><p>Age was identified to a risk factor associated to HBP in type 2 diabetes in our study (p = 0.000). Occurrence of HBP increased with age. Other authors reported similar conclusion. In this way, Dibia reported that 67% of diabetics with hypertension had age range between 51 and 70 years [<xref ref-type="bibr" rid="scirp.60653-ref6">6</xref>] ; Aassri et al. found that HBP and diabetes association was significant between 66 and 69 years [<xref ref-type="bibr" rid="scirp.60653-ref14">14</xref>] ; Ralison et al. found a pic of HBP in type 2 diabetics above 50 years and particularly between 60 and 69 years [<xref ref-type="bibr" rid="scirp.60653-ref7">7</xref>] ; according to Khochtali et al. in Tunisia, 77% of diabetics above 65 years had hypertension [<xref ref-type="bibr" rid="scirp.60653-ref15">15</xref>] . This fact would be due to modifications of vascular system observed with age. In effect, an alteration and a relative reduction of elastic fibers occur and are replaced by collagen tissue in arteries wall. This evolution induces more rigidity of arteries contributing to elevate blood pressure.</p><p>In our study, the duration of diabetes was a factor associated with hypertension in type 2 diabetes. This trend was confirmed by Dibia in Nigeria [<xref ref-type="bibr" rid="scirp.60653-ref6">6</xref>] and Motala in South Africa [<xref ref-type="bibr" rid="scirp.60653-ref16">16</xref>] . This result may be related to chronic hyperglycemia resulting in endothelial suffering leading to thickening of the arterial wall and to a rise in blood pressure later.</p><p>We found that abdominal obesity was significantly associated with the occurrence of hypertension in type 2 diabetic patients (p = 0.036). Indeed in our study, the frequency of hypertension in type 2 diabetics with abdominal obesity was 71.9% against 57.1% among those who did not have abdominal obesity. This same observation was made in the general population by Gordon et al. [<xref ref-type="bibr" rid="scirp.60653-ref17">17</xref>] . The author has dismantled that abdominal obesity is a risk factor associated with the occurrence of hypertension and type 2 diabetes.</p><p>The result of our study could be explained by the fact that type 2 diabetes was usually part of metabolic syndrome.</p><p>Our results showed no correlation between dyslipidemia and hypertension in type 2 diabetics.</p><p>Conflicting results have been reported in Japan, where a significant correlation is found between the HDL hypocholesterolemia and the occurrence of hypertension in diabetic hypertensive by Miyagi et al. [<xref ref-type="bibr" rid="scirp.60653-ref18">18</xref>] . This same observation was made in Morocco by Diyane et al. [<xref ref-type="bibr" rid="scirp.60653-ref19">19</xref>] . This could be related to the fact that all patients were unable to make or cholesterol and triglycerides.</p><p>Contrary to some published data [<xref ref-type="bibr" rid="scirp.60653-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.60653-ref19">19</xref>] , our study did not identify any microangiopathy as a factor associated with hypertension in type 2 diabetics.</p><p>According to the results of our study, history of stroke was found to be correlated with hypertension in type 2 diabetics because all diabetic patients with stroke had hypertension (p = 0.013). This observation corroborates those of Diyane et al. [<xref ref-type="bibr" rid="scirp.60653-ref19">19</xref>] and Tanguy et al. [<xref ref-type="bibr" rid="scirp.60653-ref10">10</xref>] . In addition, a meta-analysis [<xref ref-type="bibr" rid="scirp.60653-ref20">20</xref>] published in 2011 showed that in diabetic type 2, reducing the risk of stroke was proportional to the reduction in SBP.</p><p>We also identified the diabetic foot as a factor associated with hypertension in type 2 diabetics. Therefore, special monitoring of the feet will be indicated in diabetic patients with hypertension.</p></sec><sec id="s5"><title>Cite this paper</title><p>DanielAmoussou-Guenou,ArmandWanvoegbe,AnthelmeAgbodand&#233;,AlihonouDansou,YessoufouTchabi,YasmineEyiss&#232;,Arnaulde Amoussou-GuenouFandi,LatifMouss&#233;, (2015) Prevalence and Risk Factors of Hypertension in Type 2 Diabetics in Benin. Journal of Diabetes Mellitus,05,227-232. doi: 10.4236/jdm.2015.54027</p></sec><sec id="s6"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.60653-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Guarignata, L., Whiting, D.R., Beagley, J., Linnenkamp, U., Hambleton, I., Cho, N.H., et al. (2013) Global Estimates of Diabetes Prevalence in Adults for 2013 and Projection for 2035 for the IDF Diabetes Atlas. Diabetes Research and Clinical Practice, 103, 137-149.</mixed-citation></ref><ref id="scirp.60653-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Laboureau-Soares Barbosa, S., Bouhanick, B. and Marre, M. (2000) Diabetic Hypertension. Encyclopédie Médico-Chirurgicale, Endocrinologie-Nutrition, 10-366-J-10, 7 p.</mixed-citation></ref><ref id="scirp.60653-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Racine, N. (2003) High Blood Pressure in Diabetic Patients: How to Evaluate and Treat? Le Clinicien, 18, 95-102.</mixed-citation></ref><ref id="scirp.60653-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jimoh, K., Adediran, O., Agboola, S., et al. (2008) A Study of Correlation between Derived and Basic Anthropometric Indices in Type 2 Diabetes Mellitus. The Internet Journal of Endocrinology, 5, 1-6.</mixed-citation></ref><ref id="scirp.60653-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Adebisi, S.A., Oghagbon, E.K. and Jimoh, A.K. (2003) Glycated Haemoglobin and Associated Variables in Diabetics: Ilorin Experience. West African Journal of Medicine, 22, 318-320.</mixed-citation></ref><ref id="scirp.60653-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dibia, O.G. (2009) Hypertension in Patients with Type 2 Diabetes Followed in CHU Obafemi Awolowo Ile-Ife (Osun State) in Nigeria. Ph.D. Dissertation, Faculty of Medicine, Pharmacy and Dentistry, Bamako.</mixed-citation></ref><ref id="scirp.60653-ref7"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ralison</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> Aboudou II</surname><given-names> Raharimanana</given-names></name>,<name name-style="western"><surname> R.N.</surname><given-names> et al. </given-names></name>,<etal>et al</etal>. (<year>2010</year>)<article-title>Epidemiological Profile of Diabetic Hypertensive Hospitalized in Internal Medicine at the University Hospital of Mahajanga Madagascar</article-title><source> Revue électronique en sciences de la santé</source><volume> 1</volume>,<fpage> 28</fpage>-<lpage>35</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.60653-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lokrou, A. And Diallo, M.M. (2010) BP Level of Diabetics. Diabetes &amp; Metabolism, 36, A53.http://dx.doi.org/10.1016/S1262-3636(10)70207-X</mixed-citation></ref><ref id="scirp.60653-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Howards, J.N.B. and Bower Kmb, W.P. (2006) Factors Influencing the Management of Hypertension in Type 2 Diabetes. Canadian Journal of Diabetes, 30, 38-45. http://dx.doi.org/10.1016/S1499-2671(06)01004-5</mixed-citation></ref><ref id="scirp.60653-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tanguy, B. and Aboyans, V. (2012) The Management of the Diabetic Hypertensive Patient. Réalités Cardiologiques, 290, 49-53.</mixed-citation></ref><ref id="scirp.60653-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Dembele, M., Sidibe, A.T., Traore, H.A., et al. (2000) Association HBP-Diabetes Mellitus in the Internal Medicine Department of the Hospital Point G BAMAKO. Médecine d’Afrique Noire, 47, 276-280.</mixed-citation></ref><ref id="scirp.60653-ref12"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ntyonga-Pono</surname><given-names> M.P. </given-names></name>,<etal>et al</etal>. (<year>1996</year>)<article-title>High Blood Pressure in Diabetic Gabonese</article-title><source> Médecine d’Afrique Noire</source><volume> 43</volume>,<fpage> 434</fpage>-<lpage>437</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.60653-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Louda, F., Addi, H., Hallab, L., et al. (2010) Hypertension and Type 2 Diabetes. Diabetes &amp; Metabolism, 36, A53.http://dx.doi.org/10.1016/S1262-3636(10)70208-1</mixed-citation></ref><ref id="scirp.60653-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Aassri, H.E., Mghari, G.E. and Ansari, N.E. (2014) Patients with Type 2 Diabetes with Hypertension: Do They Prefer to Treat Diabetes or High Blood Pressure? Pan African Medical Journal, 17, 193.</mixed-citation></ref><ref id="scirp.60653-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Khochtali, I., Hamza, N., Baba, A., et al. (2010) Macrovascular Complication in Elderly Diabetic. Diabetes &amp; Metabolism, 36, A53. http://dx.doi.org/10.1016/S1262-3636(10)70206-8</mixed-citation></ref><ref id="scirp.60653-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Motala, A.A., Pirie, F.J. and Aaoma, G.E. (2001) Micro Vascular Complications in South African Patients with Long-Duration Diabetes Mellitus. SAMJ, 91, 987-992.</mixed-citation></ref><ref id="scirp.60653-ref17"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gordon</surname><given-names> W.M. </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>The Obesity Epidemic: Update on Global Cardiometabolic Risk</article-title><source> Actualités scientifiques</source><volume> 82</volume>,<fpage> 1</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.60653-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Miyagi, T., Muratani, H., Kimura, Y., et al. (2002) Increase in Pulse Pressure Relates to Diabetes Mellitus and Low HDL Cholesterol, but Not to Hyperlipidemia in Hypertensive Patients Aged 50 Years or Older. Hypertension Research, 25, 335-341. http://dx.doi.org/10.1291/hypres.25.335</mixed-citation></ref><ref id="scirp.60653-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Diyane, K., Ansari, N.E., Mghari, G.E., et al. (2013) The Characteristics of the Association of Type 2 Diabetes and Hypertension in the Elderly 65 Years and Older. Pan African Medical Journal, 14, 100.</mixed-citation></ref><ref id="scirp.60653-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Bangalore, S., Kumar, S., Lobach, I., et al. (2011) Blood Pressure Targets in Subjects with Type 2 Diabetes Mellitus/ Impaired Fasting Glucose: Observations from Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. Circulation, 123, 799-810. http://dx.doi.org/10.1161/CIRCULATIONAHA.110.016337</mixed-citation></ref></ref-list></back></article>